Although levo-alpha-acetylmethadol (LAAM), a derivative of methadone, has been successfully used as an alternative to methadone maintenance in opioid addicts, its effect on concurrent opioid and cocaine abuse has not been ascertained. Thus, this study proposed to examine the clinical efficacy of low- and high-dose LAAM maintenance on opioid and cocaine use in opioid-dependent cocaine abusers. In addition, since contingency management procedures have demonstrated some success in decreasing cocaine use in cocaine-abusing individuals, this study also proposes to examine the clinical efficacy of the presence or absence of contingency management procedures targeting illicit drug use. One hundred sixty male and female opioid-dependent cocaine abusers will be stratified by sex and randomly assigned to one of four treatment groups according to a 2 x 2 experiment design: low-dose LAAM (99 mg/wk) with adjunct contingency management procedures; low-dose LAAM (99 mg/wk) without adjunct contingency management procedures; high-dose LAAM (330 mg/wk) with adjunct contingency management procedures; and high-dose LAAM (330 mg/wk) without adjunct contingency management procedures. The duration of the study will be 24 weeks, with LAAM being administered on a thrice-weekly (MWF) basis. Subjects are inducted onto LAAM during weeks 1-3 and then maintained on their assigned maintenance dose (99 mg/wk or 330 mg/wk) through week 24. During maintenance, the Friday dose will be 1.3 times greater that the Monday and Wednesday dose. At the conclusion of the study, subjects undergo detoxification from LAAM over a 4 week period. For those in the contingency management procedure groups, each drug-free urine submitted will result in a voucher worth a certain monetary value that increases for consecutively drug-free urines (weeks 1-12) or a CT State lottery ticket worth $1.00 (weeks 13-24). Vouchers can be exchanged for mutually agreed upon goods and services at any time during the study. Subjects not assigned to the contingency management procedure will receive monetary vouchers (weeks 1-12) or lottery tickets (weeks 13- 24) according to a yoked-control schedule (that is, not contingent upon illicit drug abstinence). Outcome measures will include: 1) treatment retention, 2) illicit drug use, 3) self-reported adverse and opioid withdrawal symptoms, and 4) psychosocial functioning. Prognostic factors (i.e., sex, post-traumatic stress disorder, and depression), will also be examined in relation to treatment outcome. These findings will assist in developing more effective strategies in treating individuals with combined cocaine and opioid dependence.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
5P50DA009250-05
Application #
6104090
Study Section
Project Start
1998-09-30
Project End
1999-09-30
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
5
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Yale University
Department
Type
DUNS #
082359691
City
New Haven
State
CT
Country
United States
Zip Code
06520
Chawarski, Marek C; Fiellin, David A; O'Connor, Patrick G et al. (2007) Utility of sweat patch testing for drug use monitoring in outpatient treatment for opiate dependence. J Subst Abuse Treat 33:411-5
Chawarski, Marek C; Moody, David E; Pakes, Juliana et al. (2005) Buprenorphine tablet versus liquid: a clinical trial comparing plasma levels, efficacy, and symptoms. J Subst Abuse Treat 29:307-12
Kosten, Thomas R; Fiellin, David A; U.S. National Buprenorphine Implementation Program (2004) Buprenorphine for office-based practice: consensus conference overview. Am J Addict 13 Suppl 1:S1-7
Kosten, Thomas; Oliveto, Alison; Feingold, Alan et al. (2003) Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients. Drug Alcohol Depend 70:315-25
Sofuoglu, Mehmet; Gonzalez, Gerardo; Poling, James et al. (2003) Prediction of treatment outcome by baseline urine cocaine results and self-reported cocaine use for cocaine and opioid dependence. Am J Drug Alcohol Abuse 29:713-27
Kosten, Thomas; Poling, James; Oliveto, Alison (2003) Effects of reducing contingency management values on heroin and cocaine use for buprenorphine- and desipramine-treated patients. Addiction 98:665-71
Stine, Susan M; Southwick, Steven M; Petrakis, Ismene L et al. (2002) Yohimbine-induced withdrawal and anxiety symptoms in opioid-dependent patients. Biol Psychiatry 51:642-51
Gottschalk, C; Beauvais, J; Hart, R et al. (2001) Cognitive function and cerebral perfusion during cocaine abstinence. Am J Psychiatry 158:540-5
Jacobsen, L K; Giedd, J N; Kreek, M J et al. (2001) Quantitative medial temporal lobe brain morphology and hypothalamic-pituitary-adrenal axis function in cocaine dependence: a preliminary report. Drug Alcohol Depend 62:49-56
McCance-Katz, E F; Rainey, P M; Friedland, G et al. (2001) Effect of opioid dependence pharmacotherapies on zidovudine disposition. Am J Addict 10:296-307

Showing the most recent 10 out of 39 publications